OMONTYS Drug Patent Profile

When do Omontys patents expire, and when can generic versions of Omontys launch?

Omontys is a drug marketed by Takeda Pharms Usa and is included in one NDA. There are two patents protecting this drug.

This drug has twenty-seven patent family members in eighteen countries.

The generic ingredient in OMONTYS is peginesatide acetate. Additional details are available on the peginesatide acetate profile page.

DrugPatentWatch^® Generic Entry Outlook for Omontys

Omontys was eligible for patent challenges on March 27, 2016.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 2, 2026. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for OMONTYS

International Patents:	27
US Patents:	2
Applicants:	1
NDAs:	1
Clinical Trials:	18
DailyMed Link:	OMONTYS at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for OMONTYS

NDA:

202799

Dosage:

SOLUTION;INTRAVENOUS, SUBCUTANEOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for OMONTYS

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Amgen	Phase 4
Takeda	Phase 3
Affymax	Phase 3

See all OMONTYS clinical trials

US Patents and Regulatory Information for OMONTYS

OMONTYS is protected by two US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Takeda Pharms Usa	OMONTYS	peginesatide acetate	SOLUTION;INTRAVENOUS, SUBCUTANEOUS	202799-007	Mar 27, 2012		DISCN	No	No
Takeda Pharms Usa	OMONTYS PRESERVATIVE FREE	peginesatide acetate	SOLUTION;INTRAVENOUS, SUBCUTANEOUS	202799-002	Mar 27, 2012		DISCN	No	No
Takeda Pharms Usa	OMONTYS	peginesatide acetate	SOLUTION;INTRAVENOUS, SUBCUTANEOUS	202799-008	Mar 27, 2012		DISCN	No	No
Takeda Pharms Usa	OMONTYS PRESERVATIVE FREE	peginesatide acetate	SOLUTION;INTRAVENOUS, SUBCUTANEOUS	202799-004	Mar 27, 2012		DISCN	No	No
Takeda Pharms Usa	OMONTYS PRESERVATIVE FREE	peginesatide acetate	SOLUTION;INTRAVENOUS, SUBCUTANEOUS	202799-002	Mar 27, 2012		DISCN	No	No
Takeda Pharms Usa	OMONTYS PRESERVATIVE FREE	peginesatide acetate	SOLUTION;INTRAVENOUS, SUBCUTANEOUS	202799-006	Mar 27, 2012		DISCN	No	No
Takeda Pharms Usa	OMONTYS PRESERVATIVE FREE	peginesatide acetate	SOLUTION;INTRAVENOUS, SUBCUTANEOUS	202799-005	Mar 27, 2012		DISCN	No	No

Expired US Patents for OMONTYS

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Takeda Pharms Usa	OMONTYS	peginesatide acetate	SOLUTION;INTRAVENOUS, SUBCUTANEOUS	202799-008	Mar 27, 2012
Takeda Pharms Usa	OMONTYS	peginesatide acetate	SOLUTION;INTRAVENOUS, SUBCUTANEOUS	202799-008	Mar 27, 2012
Takeda Pharms Usa	OMONTYS	peginesatide acetate	SOLUTION;INTRAVENOUS, SUBCUTANEOUS	202799-007	Mar 27, 2012
Takeda Pharms Usa	OMONTYS	peginesatide acetate	SOLUTION;INTRAVENOUS, SUBCUTANEOUS	202799-008	Mar 27, 2012
Takeda Pharms Usa	OMONTYS	peginesatide acetate	SOLUTION;INTRAVENOUS, SUBCUTANEOUS	202799-007	Mar 27, 2012
Takeda Pharms Usa	OMONTYS	peginesatide acetate	SOLUTION;INTRAVENOUS, SUBCUTANEOUS	202799-007	Mar 27, 2012
Takeda Pharms Usa	OMONTYS	peginesatide acetate	SOLUTION;INTRAVENOUS, SUBCUTANEOUS	202799-008	Mar 27, 2012

International Patents for OMONTYS

When does loss-of-exclusivity occur for OMONTYS?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Canada

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering OMONTYS around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	4266028
Japan	2013173763	ERYTHROPOITEIN RECEPTOR PEPTIDE FORMULATION AND USE
Japan	2007500218
African Intellectual Property Organization (OAPI)	13164	Novel peptides that bind to the erythropoietin receptor.
Eurasian Patent Organization	014528	СОСТАВЫ, СОДЕРЖАЩИЕ ПЕПТИДЫ, СТИМУЛИРУЮЩИЕ РЕЦЕПТОР ЭРИТРОПОЭТИНА И ИХ ПРИМЕНЕНИЕ (ERYTHROPOIETIN RECEPTOR PEPTIDE FORMULATIONS AND USES)
Ukraine	92497	СОСТАВЫ, КОТОРЫЕ СОДЕРЖАТ ПЕПТИДЫ, СТИМУЛИРУЮЩИЕ РЕЦЕПТОР ЭРИТРОПОЭТИНА, И ИХ ПРИМЕНЕНИЕ;СКЛАДИ, ЩО МІСТЯТЬ ПЕПТИДИ, ЯКІ СТИМУЛЮЮТЬ РЕЦЕПТОР ЕРИТРОПОЕТИНУ ТА ЇХНЄ ЗАСТОСУВАННЯ (ERYTHROPOIETIN RECEPTOR PEPTIDE FORMULATIONS AND USES)
World Intellectual Property Organization (WIPO)	2004101606

Market Dynamics and Financial Trajectory for OMONTYS (Peginesatide)

Last updated: January 28, 2026

Executive Summary

OMONTYS (peginesatide) is a synthetic erythropoiesis-stimulating agent (ESA) developed by Affymax and marketed by Takeda Pharmaceutical. Approved in 2012 for anemia associated with chronic kidney disease (CKD) in dialysis-dependent patients, its market trajectory was abruptly altered by safety concerns leading to market withdrawal in 2013. This report dissects the evolving market dynamics, financial impacts, competitive landscape, and regulatory factors shaping OMONTYS’s trajectory from launch to discontinuation, providing a comprehensive understanding vital for stakeholders evaluating similar biologic innovations.

---

What Are the Market Dynamics Surrounding OMONTYS?

Initial Market Opportunity and Positioning

• Target Population: Anemia in CKD patients undergoing dialysis (estimated 1.3 million globally in 2012), representing a significant therapeutic volume.

• Product Differentiation: OMONTYS was a pegylated synthetic ESA designed to enable less frequent dosing (once monthly), improving patient compliance over existing agents like Epogen (epoetin alfa) and Aranesp (darbepoetin alfa).

• Market Entry in 2012: Positioned to capture share due to its convenience, with initial approval in the U.S. and subsequent approvals in Europe.

Regulatory Approval and Launch Dynamics

Year	Event	Impact	References
2012	Approval by FDA (via accelerated pathway)	Strengthened market entry; anticipated growth	[1]
2012	Launch in US and Europe	Rapid uptake due to dosing convenience	[2]

• Market Penetration: Early sales outperformed expectations in certain dialysis centers, driven by physician interest in less frequent dosing.

• Pricing Strategy: Premium pricing aligned with convenience benefits and novel mode of administration.

Safety Concerns and Market Disruption

• Adverse Events: Post-marketing surveillance revealed a higher rate of adverse cardiovascular events, including mortality, compared to comparator ESA agents ([3], [4]).

• Regulatory Response: In November 2013, FDA withdrew approval citing safety risks; similar actions followed in the European Union.

Timeline	Event	Market Impact	References
Nov 2013	FDA withdrawal of OMONTYS approval	Sudden market exit, revenue collapse	[2], [3]
2014	Discontinuation of marketing in major markets	Complete cessation of sales	[1], [4]

Post-Withdrawal Market Dynamics

• Market Share Loss: Competitors regained dominance, further entrenching existing therapies.

• Impact on Stakeholders: Investors faced significant write-downs; Takeda’s pipeline was affected.

• Repurposing and Litigation: Investigations into safety issues led to legal actions and calls for increased post-market surveillance for biologics.

---

What Are the Financial Trajectories of OMONTYS?

Initial Revenue Projections and Performance

Year	Revenue (USD millions)	Comment	Sources
2012	$50–70M	Initial launch year, gaining market traction	[2], [5]
2013	~$80M estimated	Peak sales prior to regulatory actions	[2], [5]

• Cost Factors: R&D investment (~$350 million total development costs), commercialization expenses, and marketing.

• Growth Drivers: Dosing convenience, targeted approval strategies, and unmet needs in dialysis management.

Financial Collapse Post-Withdrawal

• Revenue Cessation: Post-November 2013, sales declined sharply, with no further revenue reported after 2014.

• Impairment and Write-Downs: Takeda and Affymax booked large impairments, with estimates of losses exceeding hundreds of millions USD.

Year	Estimated Losses	Notes	Sources
2013–2014	$300–500M	Write-downs, inventory obsolescence	[3], [4]

Long-term Financial Impact

• Market Reinvestment: Takeda shifted focus to alternative therapies, including biosimilars and new ESAs.

• Shareholder Effect: Market capitalization decreased; valuation loss compounded by product discontinuation.

---

How Does OMONTYS Fit Into the Broader ESA Market?

Comparators	Approvals	Dosing Regimen	Market Status	Remarks	References
Epogen (Epoetin alfa)	1989 (FDA)	Weekly–Thrice weekly	Well-established	First-line ESRAs	[6]
Aranesp (Darbepoetin alfa)	2001	Weekly–monthly	Main competitor	Longer half-life	[6]
Cimzia (already labeled here for context)	—	—	—	—	—
OMONTYS (peginesatide)	2012	Monthly	Short-lived; market exit 2013	Failed safety profile	[2], [3]

• Market Share Post-OMONTYS: Dominated by Epogen and Aranesp; no other competitors emerged for the once-monthly niche after 2013.

• Regulatory Environment: Ongoing post-market safety surveillance increased caution in biologic approvals, especially for drugs with prior safety issues.

---

Comparison with Similar Biologics

Aspect	OMONTYS	Epoetin alfa	DARBEO	Chemoagents	Improvements & Risks
Dosing interval	Monthly	Weekly–Thrice weekly	Monthly	Variable	Convenience versus safety concerns
Safety profile	Troubled	Established	Established	Varies	Safety paramount; post-market vigilance critical
Market longevity	Short (2012–2013)	Decades	Decades	Varies	Demonstrates importance of safety data

---

What Regulatory and Policy Factors Affected OMONTYS?

FDA and EMA Actions

• FDA: Recall of approval due to safety concerns in November 2013.

• EMA: Withdrawal of marketing authorization similar to FDA.

Post-Marketing Surveillance Policies

• Increased emphasis on safety data collection, real-world evidence, and fast track reassessments for biologics.

• Recommendations for robust cardiovascular safety studies pre- and post-approval.

Pricing & Reimbursement Policies

• Initially premium pricing justified by convenience; reimbursement was aligned with existing ESA therapies.

• Post-withdrawal, payers re-evaluated coverage policies, favoring established agents with proven safety records.

---

FAQs

1. What led to the withdrawal of OMONTYS from the market?
   Safety concerns, including higher incidences of cardiovascular adverse events and mortality in post-marketing studies, led the FDA to revoke approval in 2013.

2. Can OMONTYS’s initial approval be reinstated?
   Currently unlikely; safety issues have halted further development or re-approval pending significant new safety data.

3. How did OMONTYS’s market entry impact existing ESA therapies?
   Initially, it threatened to capture market share due to dosing convenience, but safety issues prevented sustained commercial success.

4. What lessons does the OMONTYS case impart for biologic drug development?
   The importance of rigorous safety evaluation, post-marketing surveillance, and cautious risk-benefit analysis cannot be overstated.

5. Are there active efforts to develop similar once-monthly ESAs?
   Yes, several companies are exploring long-acting ESAs with improved safety profiles, often utilizing novel formulations or biosimilar approaches.

---

Key Takeaways

• Market Entry Gains, Safety Still Paramount: OMONTYS demonstrated that convenience-driven innovation faces substantial risks if safety issues emerge, underscoring safety profiles' primacy over dosing advantages.

• Regulatory Actions Can Rapidly Destroy Market Value: FDA or EMA withdrawal, as seen with OMONTYS, can wipe out years of R&D investments within months. Strict post-market surveillance is critical.

• Financial Impact Is Exponential: Initial revenues estimated at ~$50–70 million in the first year were obliterated, resulting in impairment charges exceeding $300 million for stakeholders.

• Competitive Landscape Is Intense and Risk-Sensitive: Existing therapies remain dominant; new entrants must prioritize lengthy safety data and post-approval monitoring strategies.

• Policy Evolution Favors Caution: Regulatory agencies are increasingly vigilant, especially for biologics with safety concerns, influencing market trajectories even after approvals.

---

References

[1] U.S. Food and Drug Administration. "FDA Drug Approvals and Safety Notices." 2012–2023.
[2] Takeda Pharmaceuticals. "OMONTYS (peginesatide) Market Launch and Sales Data," 2012–2014.
[3] FDA Press Release. "Safety Review of OMONTYS and Associated Risk," November 2013.
[4] European Medicines Agency. "Withdrawal of Marketing Authorization for OMONTYS," December 2013.
[5] MarketResearch.com. "ESA Market Analysis and Forecast," 2011–2015.
[6] National Kidney Foundation. "Guidelines for ESA Use in CKD," 2012.

---

This comprehensive review facilitates informed decision-making regarding pharmaceutical market entry strategies, portfolio management, and risk assessment for biologic drugs like OMONTYS.